Xeris Biopharma Holdings, Inc. XERS R2K
Company Overview
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Why Investors Should Care
Net profit has compounded at 33.5% per year over the last five years.
Revenue has grown at a 38.3% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $291.85M (+43.7% YoY); net profit $554.00K.
- Trailing 12 Months Year-on-year growth — revenue +38.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 38.3%, profit CAGR 33.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 38.33% |
| 1 Year: | 38.30% |
Compounded Profit Growth
| 5 Years: | 33.53% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +52.21% |
| 6 Months: | +4.41% |
| 3 Months: | +38.69% |
| 1 Month: | +19.48% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.74 · Neutral
P/E of 118.29 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 38.3% over 5 years.
- Profit CAGR of 33.5% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 118.3.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | XERS Xeris Biopharma Holdings, Inc. R2K | 8.28 | 118.29 | $1.43B | 0.00% | 10.82% | 4.05% | 38.33% | 33.53% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 9.40M | 8.05M | 8.91M | 11.06M | 22.07M | 25.31M | 29.73M | 33.20M | 38.01M | 48.32M | 40.64M | 48.06M | 54.27M | - | 60.12M | 71.54M | 74.38M | 85.81M | 83.13M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.73M | 11.90M | 11.00M | 10.95M | 10.57M |
| Gross Profit | - | - | 6.62M | - | - | 7.84M | - | - | - | - | - | - | - | - | - | - | 51.39M | 59.64M | 63.38M | 74.86M | 72.55M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.48M | 55.16M | 56.65M | 58.09M | 64.64M |
| Operating Income | - | - | -13.74M | -16.74M | -25.79M | -24.36M | -29.07M | -18.92M | -18.78M | -13.28M | -15.98M | -4.91M | -14.24M | -8.19M | -12.89M | - | -3.09M | 4.48M | 6.73M | 16.77M | 7.92M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.23M | 8.59M | 11.08M | 21.43M | 12.33M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.30M | 7.36M | 7.27M | 7.15M | 6.88M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.22M | -1.93M | 621.00K | 11.08M | 2.23M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -29.18M | -24.10M | -16.00M | -18.41M | -27.52M | -26.01M | -33.71M | -26.18M | -21.83M | -16.83M | -19.84M | -12.19M | -18.98M | -15.01M | -15.74M | - | -9.22M | -1.93M | 621.00K | 11.08M | 2.23M |
| Diluted EPS | - | - | - | -0.30 | -0.41 | -0.39 | -0.25 | -0.19 | -0.16 | -0.12 | -0.14 | -0.09 | -0.14 | -0.10 | -0.11 | - | -0.06 | -0.01 | 0.00 | 0.06 | 0.01 |
| R&D Expense | - | - | 3.88M | 4.03M | 5.38M | 5.66M | 6.25M | 3.72M | 6.04M | 4.84M | 6.09M | 5.03M | 7.82M | 5.76M | 5.89M | - | 7.75M | 8.05M | 7.48M | - | 8.78M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 20.16M | - | 110.25M | 163.91M | 203.07M | 291.85M |
| Cost of Revenue | - | - | 22.63M | 28.64M | 36.83M | 42.57M |
| Gross Profit | - | - | 87.61M | 135.27M | 166.24M | 249.28M |
| Operating Expenses | - | - | 169.55M | 179.28M | 199.88M | 224.38M |
| Operating Income | -83.55M | - | -81.94M | -44.01M | -33.65M | 24.90M |
| EBITDA | - | - | -69.31M | -23.73M | -13.99M | 42.33M |
| Interest Expense | - | - | 14.10M | 26.61M | 30.48M | 29.08M |
| Pretax Income | - | - | -96.08M | -63.50M | -57.10M | 554.00K |
| Tax Provision | - | - | -1.42M | -1.25M | -2.27M | 0 |
| Net Income | -91.14M | - | -94.66M | -62.26M | -54.84M | 554.00K |
| Diluted EPS | - | - | -0.70 | -0.45 | -0.37 | 0.00 |
| R&D Expense | 20.92M | 25.16M | 20.97M | 22.34M | 25.56M | 31.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 159.15M | - | 344.52M | 322.60M | 323.06M | 383.53M |
| Current Assets | - | - | - | 186.82M | 156.26M | 167.66M | 240.31M |
| Cash & Equivalents | 19.52M | 37.60M | - | 121.97M | 67.45M | 71.62M | 111.04M |
| Inventory | - | - | - | 24.73M | 38.84M | 48.17M | 68.67M |
| Receivables | - | - | - | 30.83M | 39.20M | 40.41M | 51.05M |
| Total Liabilities | - | 125.39M | - | 299.33M | 329.38M | 352.68M | 369.84M |
| Current Liabilities | - | 28.21M | - | 73.62M | 95.19M | 100.44M | 109.57M |
| Long Term Debt | - | 87.02M | - | 187.07M | 190.93M | 217.01M | 220.34M |
| Total Debt | - | - | - | 198.06M | 229.19M | 271.45M | 258.10M |
| Total Equity | 14.44M | 33.76M | - | 45.19M | -6.78M | -29.61M | 13.69M |
| Shares Outstanding | - | - | - | 136.27M | 138.13M | 149.43M | 166.22M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -80.56M | - | -102.89M | -47.02M | -36.98M | 28.63M |
| Investing Cash Flow | -27.41M | - | 34.46M | -6.00M | 4.88M | -696.00K |
| Financing Cash Flow | 126.06M | - | 127.47M | -1.61M | 36.17M | 11.39M |
| Capital Expenditure | -377.00K | - | -524.00K | -2.26M | -868.00K | -696.00K |
| Free Cash Flow | -80.94M | - | -103.42M | -49.29M | -37.85M | 27.93M |
| Net Change in Cash | - | - | 59.04M | -54.64M | 4.07M | 39.32M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 79.5% | 82.5% | 81.9% | 85.4% |
| Operating Margin % | -414.5% | - | -74.3% | -26.8% | -16.6% | 8.5% |
| Net Margin % | -452.2% | - | -85.9% | -38.0% | -27.0% | 0.2% |
| ROE % | -270.0% | - | -209.5% | 917.9% | 185.2% | 4.0% |
| ROCE % | -63.8% | - | -30.2% | -19.4% | -15.1% | 9.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.50% | 12.95M | $109.15M |
| 2 | Shaw D.E. & Co., Inc. | 4.51% | 7.79M | $65.67M |
| 3 | Vanguard Capital Management LLC | 4.04% | 6.98M | $58.86M |
| 4 | State Street Corporation | 2.70% | 4.66M | $39.27M |
| 5 | Geode Capital Management, LLC | 2.49% | 4.29M | $36.18M |
| 6 | Qube Research & Technologies Ltd | 2.38% | 4.11M | $34.69M |
| 7 | Rosalind Advisors, Inc. | 1.87% | 3.23M | $27.25M |
| 8 | Nuveen, LLC | 1.69% | 2.92M | $24.59M |
| 9 | Vanguard Portfolio Management LLC | 1.54% | 2.67M | $22.47M |
| 10 | Morgan Stanley | 1.49% | 2.57M | $21.69M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XERS
Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNbG8xcGtFV2VaT0p6aEJaX3lyZlUxLVNLLWZWSjB0elE3ZE42b2FNWW1FWjFra1VjMDFOVmx2OS1QQnZGMTJQY01La2l1OXUxTXJWTTFscWp3cnlqQkVUb2diYVk5cHItT3c3ajR5SEhaRzhHTGhQWkdJb1lPb0dNRDV0cmFWcC1pV0NfLW…
Enterprise value to revenue forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS - TradingView
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNNUZYWExTSkRocHUwSFpQbHpYVXFOSzNwM0lPWkZzcEdxUEpYYW9UQlN5SWRHbHZQYWZGVXdrQUxNWVg4M1lBcG1tX0plRFlhT0kxSkZGNmJOUlZFaVRjMmo5MjZkajJoQWtSRlluaTR5Z3pZNTdHQ2NKcnh5NGpLRldvWndldU5GeVFFaj…
Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right (NASDAQ:XERS) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOMDdGbkItT1ZYeFBwVnk4UVVmaEJMUHdvd2FZWGMwRWtKRnNBYk01ZHZzTkRLSlFKVlRGbzkwTzZEcHhXTzBfMmlkU1pqTDVYUGwxZUdXZHBwaWc5SGtPc2pwSHRoSE5ZWnAwN3h2bXpscWRWMXR2NUJQaTBjX1dpTURfOHN1SUFaMXNlYn…
Insider Sale: See Remarks of $XERS Sells 17,400 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOXzJISmFoWEI0aU10VmxFOGxCbnlIenRVei1CaXlVV1FYN0FoUW1fM1MtQi1MbVZmbUdnNkc4X2VYTjF6LWtxQXhnYXAxRnQ1a280azRyeWl4eTlHODViNWZTMFE1dklZU3FtcW5Dd3BLcXB0Zmx3c0tJYk9wTFhtSktTS1FUS1l0Q190Z2…
Xeris gives 47 new hires 221,323 stock awards under Nasdaq rule - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPM19iTDVucnh5b1dqSXhkS2dlMzRUSDFaRUlnd2Nqa0M2SHR1QXVqSTdVUmh3NGc5a2RZMnhTRUFkMEVhWHhfcmViMVBZV1k5TDhQdXdRemlHTS14MXNhQkVUQU9GdXNVaWFTeDNmR0JZQm9WZEpUVDJMemZRRmd2T2dZYXoxbFNzenA5a2…
Gen Xers and Millennials share the ‘distinct smells’ from the ’90s that defined the decade - Upworthy
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNU0VGOXIzRUFkaGZ4ZjBUcllVVnZhMjk1cVIzZjhTdmFjZGR3X21KMjZOVEVhWTRpU1BaT2FlSnMxYkw2bVZndDNfSXBRZG9tV1hmbjd4bzI3dTRCZ3Jqa2lzZk93cWxlaWpkSDhMTVVzU19BOEJsZUJVZUdEcENDSlFzaWtpbkhScXpvMG…
XERS — Frequently Asked Questions
What is the current share price of Xeris Biopharma Holdings, Inc. (XERS)?
As of 2026-07-14 21:23 PDT, Xeris Biopharma Holdings, Inc. (XERS) trades at $8.28 on NasdaqGS. Its 52-week range is $5.00 to $9.90.
What is the market capitalisation of XERS?
Xeris Biopharma Holdings, Inc. (XERS) has a market capitalisation of $1.43B on NasdaqGS.
What is the P/E ratio of XERS?
XERS trades at a trailing price-to-earnings (P/E) ratio of 118.29. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 102.82.
What is the return on equity (ROE) of XERS?
XERS has a return on equity (ROE) of 4.05%. Its return on capital employed (ROCE) is 10.82%.
Is XERS a good stock to buy?
This page provides a data-driven analysis of Xeris Biopharma Holdings, Inc. (XERS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.